We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,810.00 | 1,811.00 | 1,812.00 | 1,812.50 | 1,797.00 | 1,805.00 | 4,741,076 | 16:35:16 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 15.13 | 74.58B |
From May 2019 to May 2024
By Maria Armental
GlaxoSmithKline PLC's Nucala has been approved in the U.S. as an add-on treatment for children 6 to 11 years old with a severe type of asthma characterized by high levels of white blood cells, the company said Thursday.
Nucala, which contains the active substance mepolizumab, was first approved by the Food and Drug Administration in 2015 as an add-on maintenance treatment for patients with severe eosinophilic asthma at least 12 years old. It has been approved in the European Union for use as an add-on treatment for severe eosinophilic asthma in patients aged 6 and older since August 2018.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
September 12, 2019 16:27 ET (20:27 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
